(S)-2-amino-3-(4-(pyridin-3-yl)phenyl)propanoic acid | 916911-74-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-amino-3-(4-(pyridin-3-yl)phenyl)propanoic acid
• 英文别名: (2S)-2-amino-3-(4-pyridin-3-ylphenyl)propanoic acid
• CAS: 916911-74-5
• 化学式: C₁₄H₁₄N₂O₂
• 分子量: 242.277
• InChiKey: HWAKOCNTLFYOFR-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  76.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E,2S)-2-[(2S)-2-hydroxy-1,4-bis[(2-methylpropan-2-yl)oxy]-1,4-dioxobutan-2-yl]-11-oxooctadec-3-enoic acid 、 (S)-2-amino-3-(4-(pyridin-3-yl)phenyl)propanoic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 生成
  参考文献：
  名称：

  NA255作为新型靶向宿主的抗HCV药物的开发中，衍生物的对映选择性合成及其构效关系研究

  摘要：

  丙型肝炎病毒（HCV）感染代表严重的医疗保健问题。以前，我们报道了使用HCV亚基因组复制子细胞培养系统从天然产物库中鉴定出NA255。在这里，我们报告如何确定NA255的绝对立体化学，并开发了NA255衍生物的对映选择性合成方法。公开了NA255衍生物的结构活性关系和代表性化合物的大鼠药代动力学特征。

  DOI：

  10.1016/j.bmcl.2012.10.083

文献信息

• RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：The Johns Hopkins University

  公开号：US20210094933A1

  公开（公告）日：2021-04-01

  The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

  本公开提供了受免疫蛋白配体家族FK506和雷帕霉素天然产物启发的大环化合物。生成包含FK506和雷帕霉素结合结构域的Rapafucin大环化合物库，应具有作为治疗疾病新药的潜力。
• Method Of Producing Compound Having Anti-Hcv Activity
  申请人：Aoki Masahiro

  公开号：US20110098477A1

  公开（公告）日：2011-04-28

  There is provided a convenient and inexpensive method of producing a compound which has a high activity of inhibiting replication of hepatitis C virus (HCV) and is useful for preventing and treating a liver disease caused by HCV infection. It is a method of biologically producing a compound represented by the formula (1): [wherein A represents a hydrogen atom, a straight or branched alkyl group having 1 to 8 carbon atoms, or the like], or a pharmaceutically acceptable salt thereof, a method comprising adding an amino acid derivative represented by the formula (3): [wherein A has the same meaning as defined for the compound of the above formula (1); and R represents a hydrogen atom, a straight or branched alkyl group having 1 to 8 carbon atoms, or the like], or a salt thereof into the fungal mycelium or the culture medium/culture broth of a filamentous fungal strain having an ability to produce the compound represented by the formula (2): to thereby cause the fungal strain to directly produce the compound of the formula (1).

  提供了一种方便且廉价的方法，用于生产一种具有高抑制丙型肝炎病毒（HCV）复制活性的化合物，并且可用于预防和治疗由HCV感染引起的肝病。这是一种生物学生产一种由以下化学式（1）表示的化合物的方法：[其中A代表氢原子、具有1至8个碳原子的直链或支链烷基基团，或类似物]，或其药学上可接受的盐的方法，包括将由以下化学式（3）表示的氨基酸衍生物添加到具有生产由以下化学式（2）表示的化合物的能力的丝状真菌菌株的真菌菌丝或培养基/培养液中，从而使真菌菌株直接产生化合物的化学式（1）。
• Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
  申请人：——

  公开号：US20040127423A1

  公开（公告）日：2004-07-01

  The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.

  本发明提供了一种新型的人类胰高血糖素样肽-1（GLP-1）肽类模拟物，这些模拟物模拟了天然GLP-1肽的生物活性，因此可用于治疗或预防与GLP活性相关的疾病或紊乱。此外，本发明提供了新型的化学修饰肽，不仅可以刺激II型糖尿病患者的胰岛素分泌，还能产生其他有益的胰岛素促分泌反应。这些合成肽GLP-1模拟物具有较高的稳定性，不易被蛋白酶裂解，使它们成为口服或静脉注射的理想治疗候选药物。
• PROCESS FOR THE PREPARATION OF HETEROARYL-PHENYLALANINES
  申请人：——

  公开号：US20020028946A1

  公开（公告）日：2002-03-07

  1 A process for the preparation of heteroaryl-phenylalanines of formula (II) in which R is a hydrogen atom, a straight or branched C1 -C4 alkyl groups or a benzyl group; R1 is an optionally substituted 5 or 6 membered aromatic heterocyclic group with one or two heteroatoms selected among nitrogen, oxygen and sulphur; comprising a cross-coupling reaction among heteroaryl-zinc halide and phenylalanine derivatives is described. Compounds of formula (II) are intermediates useful for the preparation of compounds endowed with pharmacological activity.

  一种制备式（II）异芳基-苯丙氨酸的方法，其中R是氢原子，直链或支链C1-C4烷基或苄基；R1是一种可选取的、带有一个或两个氮、氧和硫杂原子的5或6元芳香杂环基，包括异芳基锌卤化物和苯丙氨酸衍生物的交叉偶联反应。式（II）化合物是中间体，用于制备具有药理活性的化合物。
• HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Natarajan Iyer Sesha

  公开号：US20070287670A1

  公开（公告）日：2007-12-13

  The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.

  本发明提供了新型的人类胰高血糖素样肽-1 (GLP-1) 肽类模拟物，这些模拟物模仿了天然的 GLP-1 肽的生物活性，因此可用于治疗或预防与 GLP 活性相关的疾病或疾病。此外，本发明提供了新型的化学修饰肽，这些肽不仅可以刺激 II 型糖尿病患者的胰岛素分泌，还可以产生其他有益的胰岛素促进反应。这些合成的 GLP-1 模拟物肽类表现出对蛋白酶水解的稳定性增加，使它们成为口服或静脉注射治疗的理想候选药物。